Unigene’s First Site-Directed Bone Growth Patent Issues

Share this story with your network

BOONTON, N.J.–(BUSINESS WIRE)–Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) reported that its first patent covering its Site-Directed Bone Growth (SDBG) technology has issued. The technology, jointly invented in collaboration with Dr. Agnès Vignery at the Yale School of Medicine, is designed to facilitate and accelerate bone growth at precisely targeted locations in the body using a simple surgical procedure that can be performed on an outpatient basis with minimal invasiveness. Animal studies have shown that, in combination with one or more therapeutic compounds, SDBG can grow significant amounts of high quality bone.

The claims of U.S patent #7,531,518, “Method of Fostering Bone Formation and Preservation,” provide broad protection for the inducement of rapid bone growth at specific skeletal sites and its subsequent preservation using a variety of therapeutic agents, such as parathyroid hormone, calcitonin and bisphosphonates. Several other patent applications covering the SDBG program are currently being reviewed by the U.S. Patent and Trademark Office.

Leave a Comment

Your email address will not be published. Required fields are marked *